Menu Search
Equities

Cantargia AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert
7V3:MUN

Cantargia AB

Actions
  • Price (EUR)0.5070
  • Today's Change0.00 / 0.00%
  • Shares traded5.00k
  • 1 Year change+241.87%
  • Beta1.6661
Data delayed at least 15 minutes, as of Feb 11 2026 07:02 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.

  • Revenue in SEK (TTM)308.69m
  • Net income in SEK139.93m
  • Incorporated2009
  • Employees23.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.